-DOCSTART- -X- O
Pharmacodynamic -X- _ O
studies -X- _ O
report -X- _ O
on -X- _ O
the -X- _ O
rapid -X- _ O
bactericidal -X- _ O
activity -X- _ O
of -X- _ O
aminoglycosides -X- _ B-Intervention
, -X- _ O
conferring -X- _ O
them -X- _ O
as -X- _ O
being -X- _ O
of -X- _ O
theoretical -X- _ O
interest -X- _ O
for -X- _ O
bacteraemia -X- _ O
treatment. -X- _ O
We -X- _ O
assessed -X- _ O
this -X- _ O
issue -X- _ O
in -X- _ O
a -X- _ O
retrospective -X- _ O
study -X- _ O
of -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
intensive -X- _ I-Patient
care -X- _ I-Patient
unit -X- _ I-Patient
( -X- _ I-Patient
ICU -X- _ I-Patient
) -X- _ I-Patient
-acquired -X- _ I-Patient
bacteraemias. -X- _ I-Patient
To -X- _ O
determine -X- _ O
the -X- _ O
impact -X- _ O
of -X- _ O
aminoglycosides -X- _ B-Intervention
in -X- _ O
antimicrobial -X- _ O
combination -X- _ O
on -X- _ O
the -X- _ O
outcome -X- _ O
of -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
bacteraemia -X- _ I-Patient
, -X- _ O
we -X- _ O
performed -X- _ O
a -X- _ O
monovariate -X- _ O
analysis -X- _ O
and -X- _ O
a -X- _ O
logistic -X- _ O
regression -X- _ O
analysis -X- _ O
comparing -X- _ O
patients -X- _ O
treated -X- _ O
with -X- _ O
or -X- _ O
without -X- _ O
aminoglycosides. -X- _ O
Forty-eight -X- _ B-Patient
bacteraemias -X- _ I-Patient
in -X- _ I-Patient
48 -X- _ I-Patient
patients -X- _ I-Patient
were -X- _ O
included. -X- _ O
Eighteen -X- _ B-Intervention
patients -X- _ I-Intervention
received -X- _ I-Intervention
aminoglycosides. -X- _ I-Intervention
Baseline -X- _ B-Outcome
characteristics -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
adaptation -X- _ I-Outcome
and -X- _ I-Outcome
adequation -X- _ I-Outcome
of -X- _ I-Outcome
antibiotherapy -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
differ -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
who -X- _ I-Outcome
did -X- _ I-Outcome
or -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
receive -X- _ I-Outcome
aminoglycosides. -X- _ I-Outcome
Patients -X- _ I-Outcome
who -X- _ I-Outcome
received -X- _ I-Outcome
aminoglycosides -X- _ I-Outcome
had -X- _ I-Outcome
longer -X- _ I-Outcome
time -X- _ I-Outcome
alive -X- _ I-Outcome
away -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
ICU -X- _ I-Outcome
( -X- _ I-Outcome
11.3 -X- _ I-Outcome
± -X- _ I-Outcome
8.9 -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
[ -X- _ I-Outcome
0–20 -X- _ I-Outcome
] -X- _ I-Outcome
) -X- _ I-Outcome
vs. -X- _ I-Outcome
3.2 -X- _ I-Outcome
± -X- _ I-Outcome
6.6 -X- _ I-Outcome
( -X- _ I-Outcome
0 -X- _ I-Outcome
[ -X- _ I-Outcome
0–2 -X- _ I-Outcome
] -X- _ I-Outcome
days -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.002 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
free -X- _ I-Outcome
from -X- _ I-Outcome
mechanical -X- _ I-Outcome
ventilation -X- _ I-Outcome
( -X- _ I-Outcome
12.5 -X- _ I-Outcome
± -X- _ I-Outcome
9.3 -X- _ I-Outcome
( -X- _ I-Outcome
14 -X- _ I-Outcome
[ -X- _ I-Outcome
0–21 -X- _ I-Outcome
] -X- _ I-Outcome
vs. -X- _ I-Outcome
5.5 -X- _ I-Outcome
± -X- _ I-Outcome
9.2 -X- _ I-Outcome
( -X- _ I-Outcome
0 -X- _ I-Outcome
[ -X- _ I-Outcome
0–10 -X- _ I-Outcome
] -X- _ I-Outcome
days -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.02 -X- _ I-Outcome
) -X- _ I-Outcome
on -X- _ I-Outcome
day -X- _ I-Outcome
28. -X- _ I-Outcome
The -X- _ I-Outcome
ICU -X- _ I-Outcome
mortality -X- _ I-Outcome
was -X- _ I-Outcome
16 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
aminoglycoside -X- _ I-Outcome
group -X- _ I-Outcome
versus -X- _ I-Outcome
46 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.03 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
In -X- _ I-Outcome
the -X- _ I-Outcome
multivariate -X- _ I-Outcome
analysis -X- _ I-Outcome
, -X- _ I-Outcome
patients -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
aminoglycosides -X- _ I-Outcome
were -X- _ I-Outcome
6 -X- _ I-Outcome
times -X- _ I-Outcome
less -X- _ I-Outcome
likely -X- _ I-Outcome
to -X- _ I-Outcome
die -X- _ I-Outcome
than -X- _ I-Outcome
those -X- _ I-Outcome
treated -X- _ I-Outcome
without -X- _ I-Outcome
aminoglycosides -X- _ I-Outcome
( -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
[ -X- _ I-Outcome
CI -X- _ I-Outcome
] -X- _ I-Outcome
= -X- _ I-Outcome
[ -X- _ I-Outcome
1.3–28.9 -X- _ I-Outcome
] -X- _ I-Outcome
; -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.02 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Our -X- _ O
study -X- _ O
supports -X- _ O
the -X- _ O
hypothesis -X- _ O
that -X- _ O
combination -X- _ O
short-term -X- _ O
antibiotherapy -X- _ O
with -X- _ O
an -X- _ O
aminoglycoside -X- _ O
for -X- _ O
ICU-acquired -X- _ O
bacteraemias -X- _ O
could -X- _ O
increase -X- _ O
survival -X- _ O
. -X- _ O

